The first East Coast manufacturing site for Genentech (Roche’s U.S. subsidiary) is a fill-finish biologics plant that will produce metabolic medicines, including next-gen obesity treatments, to support growing demand.

The project is part of Roche’s $50B U.S. initiative and will create more than 400 local full-time jobs when operational (2029) and about 1,500 construction jobs during development.

Gilead announced an $11 billion U.S. investment initiative (supplementing $21 billion already planned through 2030) to expand its domestic manufacturing and R&D footprint. About $4 billion will go into capital projects: three new facilities and three upgraded sites to boost U.S. production and lab capacity.

Gilead estimated this phase will create about 800 new U.S. jobs and over 2,200 indirect jobs by 2028.

A U.S. investment pledge across five years to expand research, technology, and manufacturing capabilities. BMS seeks to gain control over complex supply chains, ensuring its medicines are made closer to the patients who need them.

Committed to investing $27 billion to build four new pharmaceutical manufacturing sites in the U.S. over the next five years – which more than doubles its U.S. investment since 2020. 

Three of the planned plants will produce active pharmaceutical ingredients, while the fourth will make injectable products.  

Site locations will be announced in 2025 and will support a growing pipeline in cardiometabolic disease, oncology, immunology, and neuroscience. 

Unveiled a plan to invest over $55 billion in U.S. manufacturing, R&D, and technology by 2029 – a 25% increase in domestic investment that includes building four new advanced manufacturing facilities in the United States.  

J&J broke ground on the first facility on March 21in Wilson, North Carolina which will employ over 500 people and support ~5,000 construction jobs. The new, state-of-the art biologics manufacturing facility will significantly expand the company’s capacity to manufacture next-generation medicines for people living with cancer, immune-mediated and neurological diseases around the world.

Announced a five-year plan to spend $23 billion to build and expand 10 drug production and R&D facilities in the United States. These include constructing six new manufacturing plants and a new R&D hub in the San Diego area. Four of the plant locations are still to be decided, but two will be built in Florida and Texas to produce certain cancer therapies. 

The company will also expand 3 manufacturing facilities in Indianapolis, IN, Millburn, NJ, and Carlsbad, CA. 

These investments are expected to create more than 1,000 jobs for skilled workers like engineers and scientists as well as another 4,000 support staff and construction jobs and will enable the company to manufacture 100% of its key medicines in the U.S.

Launched a sweeping plan to invest around $50 billion across its U.S. pharmaceutical and diagnostics operations over five years. 

Roche will build multiple new facilities – including a gene therapy production plant in Pennsylvania, a new continuous glucose monitor device factory in Indiana, an AI-focused R&D center in Massachusetts and a 900,000 sq ft biologics facility for next-gen weight-loss drugs (location TBD). 

It is also expanding and upgrading existing manufacturing and distribution sites in Kentucky, Indiana, New Jersey, Oregon, and California, and enlarging R&D centers in Arizona, Indiana, and California. 

This effort will create over 12,000 U.S. jobs (1,000 directly at Roche and ~11,000 via supporting industries) and ensure Roche produces more medicines in the U.S. than it imports

4 new facilities and 3 existing pharma and diagnostic R&D centers; includes diagnostics investments (will expand its diagnostic manufacturing sites in Kentucky, Indiana, New Jersey, Oregon and California). +4,500 additional jobs through multiplier

Pledged an additional $2 billion over four years to strengthen its U.S. innovation and manufacturing infrastructure. The investment includes $1.5 billion to expand U.S. manufacturing operations and $500 million for R&D of “high-impact” innovation.